BMS will file for earlier-line use of Breyanzi in lymphoma after trial win

BMS will file for earlier-line use of Breyanzi in lymphoma after trial win

Source: 
Pharmaforum
snippet: 

Bristol-Myers Squibb has only just won FDA approval for its CAR-T Breyanzi in large B-cell lymphoma (LBCL), but is already eyeing an expansion into earlier-line therapy that could overtake rival therapies from Novartis and Gilead Sciences.